11:44 AM EST, 11/13/2025 (MT Newswires) -- Pfizer ( PFE ) said Thursday it has completed its acquisition of Metsera ( MTSR ) for about $7 billion in cash plus a contingent value right of up to $20.65 per share tied to the achievement of three specified clinical and regulatory milestones.

The transaction is expected to be dilutive to Pfizer ( PFE ) through 2030, mainly to enable further investment in several late-stage pipeline candidates, the company said.

Metsera ( MTSR ) is now a subsidiary of Pfizer ( PFE ), and its shares will cease trading on the Nasdaq Global Select Market upon the close of market on Thursday, according to a statement.

Pfizer ( PFE ) said the acquisition adds a portfolio of therapeutic candidates that are complementary to its Internal Medicine pipeline.

Price: 26.16, Change: +0.29, Percent Change: +1.10